Jubilant Pharmova · NSE: JUBLPHARMA · BSE: 530019
Q3 FY19 results · Oct–Dec 2018
Jubilant Pharmova reported revenue from operations of ₹2,377.10 crore and net profit of ₹267.52 crore for Q3 FY19 (Oct–Dec 2018), on a consolidated basis.
| Item | Q3 FY19 | Q3 FY18 | YoY | Q2 FY19 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 2,377.10 | — | — | 2,269.49 | +4.7% |
| Other income | 29.02 | — | — | 3.83 | +657.7% |
| Total income | 2,406.12 | — | — | 2,273.32 | +5.8% |
| Profit before tax | 355.61 | — | — | 301.81 | +17.8% |
| Net profit for the period | 267.52 | — | — | 209.77 | +27.5% |
| Attributable to shareholders of the company | 260.84 | — | — | 210.41 | +24.0% |
| EPS, basic (₹) | 16.74 | — | — | 13.50 | +24.0% |
| Net margin (%) | 11.3 | — | 9.2 |
| Item | Q3 FY19 | Q3 FY18 | YoY | Q2 FY19 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 859.58 | — | — | 887.27 | −3.1% |
| Other income | 4.96 | — | — | 63.80 | −92.2% |
| Total income | 864.54 | — | — | 951.07 | −9.1% |
| Profit before tax | 52.38 | — | — | 91.21 | −42.6% |
| Net profit for the period | 36.70 | — | — | 79.61 | −53.9% |
| EPS, basic (₹) | 2.30 | — | — | 5.00 | −54.0% |
| Net margin (%) | 4.3 | — | 9.0 |
Consolidated
- Filed with BSE
- 01 Feb 2019, 18:43 IST
- Board meeting
- 01 Feb 2019
- Period
- 01 Oct 2018 to 31 Dec 2018
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 01 Feb 2019, 18:43 IST
- Board meeting
- 01 Feb 2019
- Period
- 01 Oct 2018 to 31 Dec 2018
- Review status
- Unaudited
- Source
- XBRL filing on BSE